Risk factors associated with aggressive tumor phenotypes in papillary thyroid microcarcinoma: a systematic review and meta-analysis - Quiz - MDSpire

Risk factors associated with aggressive tumor phenotypes in papillary thyroid microcarcinoma: a systematic review and meta-analysis

  • By

  • Máté Orgoványi

  • Anett Rancz

  • Anca Dolhascu

  • Gergely Agócs

  • Boglárka Lilla Szentes

  • Emese Sipter

  • Péter Hegyi

  • Gábor László Kovács

  • July 2, 2026

  • 0 min

Share

Original Source(s)

Risk factors associated with aggressive tumor phenotypes in papillary thyroid microcarcinoma: a systematic review and meta-analysis

  • by Máté Orgoványi, Anett Rancz, Anca Dolhascu, Gergely Agócs, Boglárka Lilla Szentes, Emese Sipter, Péter Hegyi, Gábor László Kovács

  • July 2, 2026

Related Content

Immune and stromal remodeling underlies radiation-induced heart injury: insights from single-cell transcriptomics

ASCO26: Toni Choueiri, MD, KEYNOTE-654

Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.

  • July 1, 2026

  • 1 min
Correction: GNPAT promotes immunosuppression in hepatocellular carcinoma by activating the plasmalogen-PPARg pathway to drive M2 macrophage polarization